These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30158414)

  • 1. [Osimertinib for an Elderly Patient with Adenocarcinoma of the Lung Harboring EGFR T790M Mutation Diagnosed Using a Pleural Fluid Cell Block].
    Nakao M; Suzuki Y; Arakawa S; Sakai Y; Fujita K; Ishikawa M; Sato H; Muramatsu H
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1177-1180. PubMed ID: 30158414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring
    Masuhiro K; Shiroyama T; Suzuki H; Takata SO; Nasu S; Takada H; Morita S; Tanaka A; Morishita N; Okamoto N; Hirashima T
    Anticancer Res; 2018 Jun; 38(6):3567-3571. PubMed ID: 29848711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation.
    Niwa H; Nakahara Y; Sasaki J; Masuda N
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29866661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
    Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
    Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.
    Joo JW; Hong MH; Shim HS
    Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.
    Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer.
    Matsumoto Y; Kawaguchi T; Yamamoto N; Sawa K; Yoshimoto N; Suzumura T; Watanabe T; Mitsuoka S; Asai K; Kimura T; Yoshimura N; Kuwae Y; Hirata K
    Intern Med; 2017 Sep; 56(17):2325-2328. PubMed ID: 28794368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock.
    Ishioka K; Sasada S; Ohgino K; Sakai T; Takahashi S; Xu C; Sugihara K; Nakamura M
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1185-1187. PubMed ID: 30158416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.
    Oztan A; Fischer S; Schrock AB; Erlich RL; Lovly CM; Stephens PJ; Ross JS; Miller V; Ali SM; Ou SI; Raez LE
    Lung Cancer; 2017 Sep; 111():84-87. PubMed ID: 28838405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations.
    Nasu S; Shiroyama T; Morita S; Takata S; Takada H; Masuhiro K; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
    Intern Med; 2018 Dec; 57(24):3643-3645. PubMed ID: 30146570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
    Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
    Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung.
    Reichegger H; Jochum W; Förbs D; Hader C; Früh M
    Oncol Res Treat; 2016; 39(7-8):461-3. PubMed ID: 27486808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Ariyasu R; Nishikawa S; Uchibori K; Oh-Hara T; Yoshizawa T; Dotsu Y; Koyama J; Saiki M; Sonoda T; Kitazono S; Yanagitani N; Horiike A; Inase N; Kasahara K; Nishio M; Katayama R
    Lung Cancer; 2018 Mar; 117():1-6. PubMed ID: 29496249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
    Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
    Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
    Tsuchiya K; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Suda T
    Intern Med; 2018 Dec; 57(23):3423-3427. PubMed ID: 30101917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M-cis-C797S mutations in lung adenocarcinoma patients.
    Yang Y; Xu H; Ma L; Yang L; Yang G; Zhang S; Ai X; Zhang S; Wang Y
    Cancer Med; 2021 Dec; 10(23):8328-8337. PubMed ID: 34612594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
    Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA
    J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
    Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
    Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
    Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.